Document is current

Article History

Received: 12 February 2025

Accepted: 9 May 2025

First Online: 17 July 2025

Declarations

:

: This study conforms to the Declaration of Helsinki and was approved by the Regional Ethics Committee, Helse Sør-Øst (approval numbers 2015/1337/REK Sør-Øst A and 11744), and the Norwegian Data Inspectorate (Datatilsynet). The Regional Ethics Committee, Helse Sør-Øst, waived the need for informed consent from the patients included in the study, given that the study only used data that had already been collected.

: Not applicable.

: K.I.B. has received grants to his institution from AstraZeneca for this study and for lectures and consulting from Novo Nordisk, Sanofi, Lilly, Boehringer Ingelheim and Merck Sharp & Dohme. K.A.S. has received speaking honoraria from AstraZeneca, Novo Nordisk, Sanofi, Eli Lilly and Boehringer Ingelheim. T.G.J. has received lecture fees from NovoNordisk, Boehringer Ingelheim, AstraZeneca, Eli Lilly, Bayer Pharmaceuticals. M.T. holds a full-time position by an independent statistical consultant company, Statisticon AB, Uppsala, Sweden, of which AstraZeneca Nordic is a client. J.B. holds a full-time position at AstraZeneca as an epidemiologist.